2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 867

Events That Trigger the Onset of the Fibromyalgia Syndrome (FMS)
Abstract Number: 1789

Evidence for an Additive Effect of Tumor Necrosis Factor Alpha and Hypoxia to Promote Bone Destruction in Arthritis
Abstract Number: 1615

Evidence for Distinct Roles of Environmental and Genetic Factors in the Emergence of Anti Citrullinated-Protein Antibodies Positive Rheumatoid Arthritis-an Epidemiological Investigation in Twins
Abstract Number: 2164

Evidence for NF-Kb Intracellular Signaling Involvement Following CTLA4-Ig (Abatacept) Treatment of Human Macrophages
Abstract Number: 594

Evidence of Human Leucozyte Antigen-B27 in Healthy Individuals and Patients with Uveitis Is a Risk Factor for Alterations in Bone Metabolism
Abstract Number: 997

Evidence of Novel Genetic Predictors of Methotrexate Efficacy in Rheumatoid Arthritis
Abstract Number: 2450

Evoked Pain Brain Response Is Associated with Reduced μ-Opioid Receptor Binding in Fibromyalgia
Abstract Number: 596

Evolution of Atherosclerosis in Psoriatic Arthritis: Is the Former an Independent Inflammatory Process?
Abstract Number: 1688

Evolution of Preclinical Autoimmunity in Individuals At Risk for Development of Rheumatoid Arthritis
Abstract Number: 1787

Evolution of the Cytokine and Chemokine Profile in Patients Receiving Oral Daily Vitamin D: Results From a Randomized Controlled Trial
Abstract Number: 2341

Exacerbation of Collagen-Induced Arthritis by an Anti-CD3 Antibody Targeting Aminoterminal-Deficient CD3ε
Abstract Number: 2694

Examination of a Multidimensional Model of Disability and Role Functioning in Patients with Rheumatoid Arthritis
Abstract Number: 581

Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis
Abstract Number: 241

Excess Body Weight and 4-Year Function Outcomes: Comparison of African-Americans and Caucasians in the Osteoarthritis Initiative
Abstract Number: 624

Excess Health Care Utilization Prior to Diagnosis of Systemic Lupus Erythematosus in England

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].